Deletion of atrophy enhancing genes fails to ameliorate the phenotype in a mouse model of spinal muscular atrophy

Neuromuscular Disorders

Volumn 24, Issue 5, 2014, Pages 436-444

  Iyer, Chitra C ^a   McGovern, Vicki L ^a   Wise, Dawnne O ^a   Glass, David J ^b   Burghes, Arthur H M ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

MAFbx (Atrogin1); MuRF1 (Trim63); Muscle atrophy F box; Muscle RING Finger 1; Muscle ubiquitin ligases; Spinal muscular atrophy (SMA)

Indexed keywords

ATROGIN 1; MUSCLE RING FINGER 1 PROTEIN; FBXO32 PROTEIN, MOUSE; MUSCLE PROTEIN; SMN1 PROTEIN, MOUSE; SURVIVAL MOTOR NEURON PROTEIN 1; TRIM63 PROTEIN, MOUSE; UBIQUITIN PROTEIN LIGASE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DENERVATION; GASTROCNEMIUS MUSCLE; GENE; GENE DELETION; GENE EXPRESSION; HETEROZYGOTE; MAFBX GENE; MOLECULAR DYNAMICS; MOUSE; MURF1 GENE; MURF3 GENE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SPINAL MUSCULAR ATROPHY; SURVIVAL RATE; SURVIVAL TIME; UPREGULATION; ANIMAL; DEFICIENCY; DISEASE MODEL; GENETICS; HEART MUSCLE; METABOLISM; MUSCLE ATROPHY; PATHOLOGY; SKELETAL MUSCLE; SURVIVAL; TRANSGENIC MOUSE;

ANIMALS; BODY WEIGHT; DISEASE MODELS, ANIMAL; MICE, TRANSGENIC; MUSCLE FIBERS, SKELETAL; MUSCLE PROTEINS; MUSCLE, SKELETAL; MUSCULAR ATROPHY; MUSCULAR ATROPHY, SPINAL; MYOCARDIUM; PHENOTYPE; SKP CULLIN F-BOX PROTEIN LIGASES; SURVIVAL ANALYSIS; SURVIVAL OF MOTOR NEURON 1 PROTEIN; UBIQUITIN-PROTEIN LIGASES;

EID: 84899093981     PISSN: 09608966     EISSN: 18732364     Source Type: Journal    
DOI: 10.1016/j.nmd.2014.02.007     Document Type: Article

References (50)

1. Burghes A.H., Beattie C.J. Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick?. Nat Rev Neurosci 2009, 2009(10):597-609. 10.1038/nrn2670. Epub.
2. Prior T.W., Snyder P.J., Rink B.D., et al. Newborn and carrier screening for spinal muscular atrophy. Am J Med Genet Part A 2010, 152A:1608-1616.
3. Sugarman E.A., Nagan N., Zhu H., et al. Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72,400 specimens. Eur J Hum Genet EJHG 2012, 20:27-32.
4. Lefebvre S., Burglen L., Reboullet S., et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995, 80:155-165.
5. Monani U.R., Lorson C.L., Parsons D.W., et al. A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. Hum Mol Genet 1999, 8:1177-1183.
6. Lorson C.L., Hahnen E., Androphy E.J., et al. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci USA 1999, 96:6307-6311.
7. Cartegni L., Krainer A.R. Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1. Nat Genet 2002, 30:377-384.
8. Gennarelli M., Lucarelli M., Capon F., et al. Survival motor neuron gene transcript analysis in muscles from spinal muscular atrophy patients. Biochem Biophys Res Commun 1995, 213:342-348.
9. Lorson C.L., Strasswimmer J., Yao J.M., et al. SMN oligomerization defect correlates with spinal muscular atrophy severity. Nat Genet 1998, 19:63-66.
10. Lorson C.L., Androphy E.J. An exonic enhancer is required for inclusion of an essential exon in the SMA-determining gene SMN. Hum Mol Genet 2000, 9:259-265.
11. Burnett B.G., Munoz E., Tandon A., et al. Regulation of SMN protein stability. Mol Cell Biol 2009, 29:1107-1115.
12. McGovern V.L., Gavrilina T.O., Beattie C.E., et al. Embryonic motor axon development in the severe SMA mouse. Hum Mol Genet 2008, 17:2900-2909.
13. Burghes A.H. When is a deletion not a deletion? When it is converted. Am J Hum Genet 1997, 61:9-15.
14. McAndrew P.E., Parsons D.W., Simard L.R., et al. Identification of proximal spinal muscular atrophy carriers and patients by analysis of SMNT and SMNC gene copy number. Am J Hum Genet 1997, 60:1411-1422.
15. Schrank B., Gotz R., Gunnersen J.M., et al. Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos. Proc Natl Acad Sci USA 1997, 94:9920-9925.
16. Coovert D.D., Le T.T., McAndrew P.E., et al. The survival motor neuron protein in spinal muscular atrophy. Hum Mol Genet 1997, 6:1205-1214.
17. Lefebvre S., Burlet P., Liu Q., et al. Correlation between severity and SMN protein level in spinal muscular atrophy. Nat Genet 1997, 16:265-269.
18. Monani U.R., Sendtner M., Coovert D.D., et al. The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn(-/-) mice and results in a mouse with spinal muscular atrophy. Hum Mol Genet 2000, 9:333-339.
19. Hsieh-Li H.M., Chang J.G., Jong Y.J., et al. A mouse model for spinal muscular atrophy. Nat Genet 2000, 24:66-70.
20. Le T.T., Pham L.T., Butchbach M.E., et al. SMNDelta7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN. Hum Mol Genet 2005, 14:845-857.
21. Engvall E., Wewer U.M. The new frontier in muscular dystrophy research: booster genes. FASEB J 2003, 17:1579-1584.
22. Bosboom W, Vrancken AF, van den Berg LH, Wokke JH, Iannaccone ST. Drug treatment for spinal muscular atrophy types II and III. The Cochrane database of systematic reviews 2009:CD006282.
23. Rose F.F., Mattis V.B., Rindt H., et al. Delivery of recombinant follistatin lessens disease severity in a mouse model of spinal muscular atrophy. Hum Mol Genet 2009, 18:997-1005.
24. Sumner C.J., Wee C.D., Warsing L.C., et al. Inhibition of myostatin does not ameliorate disease features of severe spinal muscular atrophy mice. Hum Mol Genet 2009, 18:3145-3152.
25. Porensky P.N., Mitrpant C., McGovern V.L., et al. A single administration of morpholino antisense oligomer rescues spinal muscular atrophy in mouse. Hum Mol Genet 2012, 21:1625-1638.
26. Passini M.A., Bu J., Richards A.M., et al. Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci Transl Med 2011, 3:72ra18.
27. Foust K.D., Wang X., McGovern V.L., et al. Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotechnol 2010, 28:271-274.
28. Dominguez E., Marais T., Chatauret N., et al. Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice. Hum Mol Genet 2011, 20:681-693.
29. Le T.T., McGovern V.L., Alwine I.E., et al. Temporal requirement for high SMN expression in SMA mice. Hum Mol Genet 2011, 20:3578-3591.
30. Lutz C.M., Kariya S., Patruni S., et al. Postsymptomatic restoration of SMN rescues the disease phenotype in a mouse model of severe spinal muscular atrophy. J Clin Invest 2011, 121:3029-3041.
31. Bodine S.C., Latres E., Baumhueter S., et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 2001, 294:1704-1708.
32. Perera S., Holt M.R., Mankoo B.S., et al. Developmental regulation of MURF ubiquitin ligases and autophagy proteins nbr1, p62/SQSTM1 and LC3 during cardiac myofibril assembly and turnover. Develop Biol 2011, 351:46-61.
33. Lecker S.H., Solomon V., Mitch W.E., et al. Muscle protein breakdown and the critical role of the ubiquitin-proteasome pathway in normal and disease states. J Nutr 1999, 129:227S-237S.
34. Glass D.J. Skeletal muscle hypertrophy and atrophy signaling pathways. Int J Biochem Cell Biol 2005, 37:1974-1984.
35. Glass D.J. Signaling pathways perturbing muscle mass. Curr Opin Clin Nutr Metab Care 2010, 13:225-229.
36. Tintignac L.A., Lagirand J., Batonnet S., et al. Degradation of MyoD mediated by the SCF (MAFbx) ubiquitin ligase. J Biol Chem 2005, 280:2847-2856.
37. Li H.H., Kedar V., Zhang C., et al. Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex. J Clin Invest 2004, 114:1058-1071.
38. Cohen S., Brault J.J., Gygi S.P., et al. During muscle atrophy, thick, but not thin, filament components are degraded by MuRF1-dependent ubiquitylation. J Cell Biol 2009, 185:1083-1095.
39. Kedar V., McDonough H., Arya R., et al. Muscle-specific RING finger 1 is a bona fide ubiquitin ligase that degrades cardiac troponin I. Proc Natl Acad Sci USA 2004, 101:18135-18140.
40. McElhinny A.S., Kakinuma K., Sorimachi H., et al. Muscle-specific RING finger-1 interacts with titin to regulate sarcomeric M-line and thick filament structure and may have nuclear functions via its interaction with glucocorticoid modulatory element binding protein-1. J Cell Biol 2002, 157:125-136.
41. Bricceno K.V., Sampognaro P.J., Van Meerbeke J.P., et al. Histone deacetylase inhibition suppresses myogenin-dependent atrogene activation in spinal muscular atrophy mice. Hum Mol Genet 2012, 21:4448-4459.
42. Gavrilina T.O., McGovern V.L., Workman E., et al. Neuronal SMN expression corrects spinal muscular atrophy in severe SMA mice while muscle-specific SMN expression has no phenotypic effect. Hum Mol Genet 2008, 17:1063-1075.
43. Perera S., Mankoo B., Gautel M. Developmental regulation of MURF E3 ubiquitin ligases in skeletal muscle. J Muscle Res Cell Motility 2012, 33:107-122.
44. Bevan A.K., Hutchinson K.R., Foust K.D., et al. Early heart failure in the SMNDelta7 model of spinal muscular atrophy and correction by postnatal scAAV9-SMN delivery. Hum Mol Genet 2010, 19:3895-3905.
45. Heier C.R., Satta R., Lutz C., et al. Arrhythmia and cardiac defects are a feature of spinal muscular atrophy model mice. Hum Mol Genet 2010, 19:3906-3918.
46. Shababi M., Habibi J., Yang H.T., et al. Cardiac defects contribute to the pathology of spinal muscular atrophy models. Hum Mol Genet 2010, 19:4059-4071.
47. Dubowitz V., Sewry C.A., Fitzsimons R.B. Muscle biopsy: a practical approach 1985, Baillière Tindall, Eastbourne, xiv, 720 p. 2nd ed.
48. Hausmanowa-Petrusewicz I., Karwanska A. Electromyographic findings in different forms of infantile and juvenile proximal spinal muscular atrophy. Muscle Nerve 1986, 9:37-46.
49. Lewelt A., Krosschell K.J., Scott C., et al. Compound muscle action potential and motor function in children with spinal muscular atrophy. Muscle Nerve 2010, 42:703-708.
50. Avila A.M., Burnett B.G., Taye A.A., et al. Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy. J Clin Invest 2007, 117:659-671.